Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings

Set Alert for Sales & Earnings

Biogen’s Q3 Aduhelm Sales Even Worse Than Expected

Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.  

Launches Market Access

Roche Boosted By COVID-19 Antibody Revenues As Pandemic Recovery Progresses

Ronapreve and Actemra for COVID-19 indications padded the top-line. Roche raised its financial outlook for the year to mid-single digit growth.

Sales & Earnings Coronavirus COVID-19

J&J Expects A Commercial COVID-19 Vaccine Market By Late 2022/2023

The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.

Sales & Earnings Coronavirus COVID-19

Stock Watch: Third-Quarter Earnings Season – The New Endemic Normal

With the latest Delta variant wave in the rear-view mirror, vaccine and antiviral sales, and their impact on full-year guidance, are likely to remain the big swing factors in third-quarter earnings season.

Stock Watch Sales & Earnings

Q3 Headwinds For Pharma Could Dampen A Continued Rally

COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.

Sales & Earnings Business Strategies

Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma

Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.

Politics Policy

Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters

The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.

Launches Sales & Earnings

Stock Watch: Moderna Shares Soar While Pfizer Slides

The stock price performances of the top two coronavirus vaccine producers are inversely correlated to their sales and pipelines. There seems to be an expectation of declining coronavirus vaccine sales for some, but not for others.

Stock Watch Coronavirus COVID-19

Some Winners Emerge Despite China’s Reimbursement Price-Cutting Scheme

Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.

China Sales & Earnings

Stock Watch: Oncology After The Pandemic

Big pharmaceutical franchises may be recovering from the pandemic, but the extent of the untreated backlog of cancer patients from 2020 is still an important unknown driver even after second-quarter earnings season, and smaller cancer companies may still be bearing the brunt of COVID-19’s effects.

Stock Watch Commercial

One-Offs Boost Japan's Top Firms In Mixed Q1

Japan's top pharma firms benefited in several cases from one-off factors in what was a generally positive fiscal first quarter, but most full-year guidance remains unchanged for now.

Japan Companies

Vyepti Sales Disappoint But Lundbeck Sees Growth From Expanded Infusion Center Network

Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.

Sales & Earnings Companies
UsernamePublicRestriction

Register